Response to immune protein determines pathology of multiple sclerosisOctober 14, 2008New research may help reveal why different parts of the brain can come under attack in patients with multiple sclerosis (MS). According to a new study in mice with an MS-like disease, the brain's response to a protein produced by invading T cells dictates whether it's the spinal cord or cerebellum that comes under fire. The study-from researchers at the University of Maryland School of Medicine in Baltimore and Washington University in St. Louis-will be published online on October 13th in the Journal of Experimental Medicine. In most MS patients, the disease primarily affects the spinal cord and the white matter of the brain. But a small percentage of patients develop an atypical form of the disease, which primarily affects the cerebellum-the part of the brain that controls sensory perception and movement. For these patients, the disease tends to progress more rapidly and the prognosis is particularly bleak. MS ensues when the body's T cells invade the brain and trigger nerve-damaging inflammation, in part by secreting proteins called cytokines. According to the new study, lead by Washington University scientist John Russell, the brain's response to one particular immune protein, called interferon-g (IFNg), determines which part of the brain the T cells attack. In mice that are oblivious to IFNg (because they lack its receptor), mice suffer cerebellum and brain stem inflammation, but their spinal cords are spared. When IFNg receptors were left intact, the reverse occurred.
Exactly how the brain's response to IFNg directs the T cell attack is not yet known, but the authors suspect that IFNg triggers a localized production of T cell-attracting proteins in the spinal cord. Translating the details of the "conversation" between T cells and brain cells, suggests Russell, might bring scientists closer to understanding the variable manifestations of human MS. Rockefeller University Press | |||||||||||||||||||||
|
Related Multiple Sclerosis Current Events and Multiple Sclerosis News Articles Vitamin D deficiency in infants and nursing mothers carries long-term disease risks Once believed to be important only for bone health, vitamin D is now seen as having a critical function in maintaining the immune system throughout life. MRI scans can predict effects of MS flare-ups on optic nerve One of the most pernicious aspects of multiple sclerosis (MS) - its sheer unpredictability - may finally be starting to yield to advanced medical imaging techniques. Melatonin may save eyesight in inflammatory disease Current research suggests that melatonin therapy may help treat uveitis, a common inflammatory eye disease. The related report by Sande et al., "Therapeutic Effect of Melatonin in Experimental Uveitis," appears in the December issue of The American Journal of Pathology. Researcher tricks immune system in diabetic mice The body's immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it. In the war against diseases, nerve cells need their armor In a new study, researchers at the Montreal Neurological Institute (MNI), McGill University, and the Université de Montréal have discovered an essential mechanism for the maintenance of the normal structure of myelin, the protective covering that insulates and supports nerve cells (neurons). Intraspinal implant of mesenchymal stem cells may not heal the demyelinated spinal cord Multiple sclerosis is a disease caused by the loss of the myelinated sheath surrounding the nerve fibers of the spinal cord. Multiple sclerosis research charges ahead with new mouse model of disease A new study highlights the role of a charge-switching enzyme in nervous system deficits characteristic of multiple sclerosis and other related neurological illness. Lung airway cells activate vitamin D and increase immune response Vitamin D is essential to good health but needs to be activated to function properly in the human body. Until recently, this activation was thought to happen primarily in the kidneys, but a new University of Iowa study finds that the activation step can also occur in lung airway cells. Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows Investigators combing the genome in the hope of finding genetic variants responsible for triggering early-onset diabetes may be looking in the wrong place, new research at the Stanford University School of Medicine suggests. Phase IIb data show that BG-12 significantly reduced brain lesions in multiple sclerosis Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p<0.0001). More Multiple Sclerosis Current Events and Multiple Sclerosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||